Ophthotech Could Receive $1B+ in Novartis Eye Drug Agreement

According to a Reuters article, Ophthotech Corp. could potentially receive more than $1 billion in payments as part of a licensing deal for its experimental eye drug with Novartis AG. The company said that a unit of Novartis will market its lead experimental eye drug, Fovista, outside the United States.

Ophthotech said it could receive immediate and near-term milestone payments of up to $330 million and is eligible to get ex-US marketing approval and sales milestone payments of up to $700 million. Read the full story

More News:

All news »

What are your comments?

You cannot post comments until you have logged in. Login Here.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments